S
Steve Lu
Researcher at Howard Hughes Medical Institute
Publications - 7
Citations - 5287
Steve Lu is an academic researcher from Howard Hughes Medical Institute. The author has contributed to research in topics: Cancer & Immune checkpoint. The author has an hindex of 6, co-authored 7 publications receiving 3447 citations. Previous affiliations of Steve Lu include Swim Across America & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le,Dung T. Le,Jennifer N. Durham,Jennifer N. Durham,Kellie N. Smith,Hao Wang,Bjarne Bartlett,Bjarne Bartlett,Laveet K. Aulakh,Laveet K. Aulakh,Steve Lu,Steve Lu,Holly Kemberling,Cara Wilt,Brandon Luber,Fay Wong,Fay Wong,Nilofer S. Azad,Agnieszka A. Rucki,Daniel A. Laheru,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Tim F. Greten,Austin G. Duffy,Kristen K. Ciombor,Aleksandra Eyring,Bao H. Lam,Andrew K. Joe,S. Peter Kang,Matthias Holdhoff,Ludmila Danilova,Leslie Cope,Christian F. Meyer,Shibin Zhou,Shibin Zhou,Richard M. Goldberg,Deborah K. Armstrong,Katherine M. Bever,Amanda N. Fader,Janis M. Taube,Franck Housseau,David Spetzler,Nianqing Xiao,Drew M. Pardoll,Nickolas Papadopoulos,Nickolas Papadopoulos,Kenneth W. Kinzler,Kenneth W. Kinzler,James R. Eshleman,Bert Vogelstein,Bert Vogelstein,Robert A. Anders,Robert A. Anders,Luis A. Diaz,Luis A. Diaz +57 more
TL;DR: Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).
Journal ArticleDOI
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu,Julie E. Stein,David L. Rimm,Daphne Wang,J. Michael Bell,Douglas B. Johnson,Jeffrey A. Sosman,Kurt A. Schalper,Robert A. Anders,Hao Wang,Clifford Hoyt,Drew M. Pardoll,Ludmila Danilova,Janis M. Taube +13 more
TL;DR: A meta-analysis of studies that examined the use of PD-L1 IHC, TMB, GEP, and mIHC/IF assays to determine objective response to anti-PD-1/PD- L1 therapy found multiplex immunohistochemistry/IF and multimodality biomarker strategies appear to be associated with improved performance.
Journal ArticleDOI
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.
Changzheng Lu,Junhong Guan,Steve Lu,Qihuang Jin,Benoit Rousseau,Tianshi Lu,Dennis Stephens,Hongyi Zhang,Jiankun Zhu,Mingming Yang,Zhenhua Ren,Yong Liang,Zhida Liu,Chuanhui Han,Longchao Liu,Xuezhi Cao,Anli Zhang,Jian Qiao,Kimberly Batten,Mingyi Chen,Diego H. Castrillon,Tao Wang,Bo Li,Luis A. Diaz,Guo Min Li,Yang Xin Fu +25 more
TL;DR: Using tumor models defective in the MMR gene Mlh1, it is shown that dMLH1 tumor cells accumulate cytosolic DNA and produce IFN-β in a cGAS-STING-dependent manner, which renders d MLH1 tumors slowly progressive and highly sensitive to checkpoint blockade.
Journal ArticleDOI
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
Benoit Rousseau,Michael B. Foote,Steven Brad Maron,Bill H. Diplas,Steve Lu,Guillem Argilés,Andrea Cercek,Luis A. Diaz +7 more
TL;DR: The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA as discussed by the authors, which is the highest level of mutational burden.
Journal ArticleDOI
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.
Andrew Georgiadis,Jennifer N. Durham,Laurel Keefer,Bjarne Bartlett,Bjarne Bartlett,Magdalena Zielonka,Derek Murphy,James R. White,Steve Lu,Ellen L. Verner,Finey Ruan,David R. Riley,Robert A. Anders,Erika Gedvilaite,Samuel V. Angiuoli,Siân Jones,Victor E. Velculescu,Dung T. Le,Luis A. Diaz,Mark Sausen +19 more
TL;DR: These analyses demonstrate the feasibility of noninvasive pan-cancer screening and monitoring of patients who exhibit MSI or TMB-High and have a high likelihood of responding to immune checkpoint blockade.